Silo Pharma, Inc. SILO
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-1.23
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $72,102 | -$4.2M | $27,807 | — | $6.3M |
| 2024 | $72,102 | -$4.4M | $66,264 | — | $5.0M |
| 2023 | $72,102 | -$3.7M | $66,264 | — | $6.2M |
| 2022 | $72,102 | -$3.9M | $66,264 | — | $10.3M |
| 2021 | — | $3.9M | $66,260 | — | $9.1M |
| 2020 | $40,923 | -$3.0M | -$135,203 | — | $1.3M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Weisblum Eric | Chief Executive Officer | 2025-12-15 | Buy | 2,500 | $0.42 |
| Weisblum Eric | Chief Executive Officer | 2025-12-15 | Buy | 2,500 | $0.41 |
| Weisblum Eric | Chief Executive Officer | 2025-11-21 | Buy | 1,000 | $0.36 |
| Weisblum Eric | Chief Executive Officer | 2025-11-20 | Buy | 1,000 | $0.37 |
| Weisblum Eric | Chief Executive Officer | 2025-11-19 | Buy | 4,500 | $0.41 |
| Weisblum Eric | Chief Executive Officer | 2025-11-18 | Buy | 7,500 | $0.40 |
| Weisblum Eric | Chief Executive Officer | 2025-05-27 | Buy | 10,000 | $0.43 |
| Weisblum Eric | CEO and President | 2024-12-13 | Buy | 2,500 | $0.84 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -1.23 (distress)
- Working capital / assets 0.886
- Retained earnings / assets -2.563
- EBIT / assets -0.563
- Equity / liabilities 4.852
Source: SEC EDGAR filings · CIK 0001514183 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.